

Opportunistic infections after alemtuzumab:

New cases of norcardial infection and cytomegalovirus syndrome

Wallace J Brownlee ¹

Jeremy Chataway ^{1, 2}

¹ Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute
of Neurology, London, UK

² National Hospital for Neurology and Neurosurgery, London, UK

Alemtuzumab is an anti-CD52 monoclonal antibody that produces rapid depletion of B and T lymphocytes and other immune cells expressing the CD52 glycoprotein.¹ Lymphocyte counts fall rapidly after treatment and steadily increase over the next 6-12 months.¹ In phase III trials of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), serious infections were surprisingly uncommon given the profound and sustained period of lymphopenia.^{2, 3} Opportunistic infections including oesophageal candidiasis³, reactivation of latent tuberculosis^{2, 3}, listeria meningitis⁴ and cerebral nocardiasis⁵ have been reported, though rarely.

In this issue of *Multiple Sclerosis Journal* further cases are reported of early opportunistic infections in RRMS patients receiving alemtuzumab. Clerico and colleagues describe two patients who developed cytomegalovirus (CMV) syndrome within the first month after alemtuzumab, with fever and evidence of CMV-DNA in blood samples. The patients improved after treatment with ganciclovir and valganciclovir. Sheikh-Taha and Cormon describe a patient with RRMS who developed pulmonary nocardiasis five weeks after receiving alemtuzumab. The patient improved on treatment with meropenem. A case of fulminant cerebral nocardiasis was also recently reported in an RRMS patient treated with alemtuzumab.⁵

Neurologists treating patients with alemtuzumab need to be vigilant to possible opportunistic infections, particularly in the first few months after treatment. Based on experience in phase III trials these appear to be rare^{2, 3}, but as alemtuzumab is used increasingly in routine clinical practice, including in patients with medical co-morbidities, greater exposure to previous disease-modifying treatments, and more disability, the incidence of serious infections may rise. Moreover infections like CMV and nocardiasis need to be actively considered, since outside the setting of immunosuppression they are not common. Phase IV post-authorisation

studies are underway that will be helpful in clarifying the frequency of these potentially serious adverse events in the real-world setting. Neurologists treating MS with potent agents need to expect the unexpected.

References

1. Hartung HP, Aktas O and Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. *Mult Scler*. 2015; 21: 22-34.
2. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet*. 2012; 380: 1819-28.
3. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*. 2012; 380: 1829-39.
4. Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis - report of two cases. *Int J Mol Sci*. 2015; 16: 14669-76.
5. Penkert H, Delbridge C, Wantia N, Wiestler B and Korn T. Fulminant central nervous system Nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. *JAMA Neurol*. 2016; 73: 757-9.